{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:09:03Z","timestamp":1782385743479,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T00:00:00Z","timestamp":1434067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00198-015-3179-x","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T13:55:13Z","timestamp":1434030913000},"page":"2763-2771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3\u00a0years"],"prefix":"10.1007","volume":"26","author":[{"given":"S.","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lippuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zapalowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"T\u00f6rring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. S.","family":"Daizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. D.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"Wagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Libanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,12]]},"reference":[{"key":"3179_CR1","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","volume":"20","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20:1633\u20131650","journal-title":"Osteoporos Int"},{"key":"3179_CR2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521","journal-title":"JAMA"},{"key":"3179_CR3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1210\/jc.2013-3461","volume":"99","author":"D Bliuc","year":"2014","unstructured":"Bliuc D, Nguyen TV, Eisman JA, Center JR (2014) The impact of non-hip non-vertebral fractures in elderly women and men. J Clin Endocrinol Metab 99:415\u2013423","journal-title":"J Clin Endocrinol Metab"},{"key":"3179_CR4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"3179_CR5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, Trial HPF (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"3179_CR6","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"3179_CR7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"3179_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u2013254","journal-title":"J Bone Miner Res"},{"key":"3179_CR9","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, Group FR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"3179_CR10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120\u2013126","journal-title":"Bone"},{"key":"3179_CR11","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis\u2014where do we go from here? N Engl J Med 366:2048\u20132051","journal-title":"N Engl J Med"},{"key":"3179_CR12","first-page":"253","volume":"8","author":"L Cavalli","year":"2012","unstructured":"Cavalli L, Brandi ML (2012) Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag 8:253\u2013266","journal-title":"Ther Clin Risk Manag"},{"key":"3179_CR13","doi-asserted-by":"crossref","unstructured":"McClung MR (2013) Denosumab. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. John Wiley & Sons, pp 420\u2013424","DOI":"10.1002\/9781118453926.ch50"},{"key":"3179_CR14","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellstrom D, Radominski SC, Reginster JY, Resch H, Roman Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483\u20134492","journal-title":"J Clin Endocrinol Metab"},{"key":"3179_CR15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellstrom D, Radominski SC, Reginster JY, Resch H, Roman Ivorra JA, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694\u2013701","journal-title":"J Bone Miner Res"},{"key":"3179_CR16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","volume":"27","author":"M Austin","year":"2012","unstructured":"Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR, Trial F (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27:687\u2013693","journal-title":"J Bone Miner Res"},{"key":"3179_CR17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","volume":"16","author":"MA Bolognese","year":"2013","unstructured":"Bolognese MA, Teglbjaerg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, Hoiseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C (2013) Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 16:147\u2013153","journal-title":"J Clin Densitom"},{"key":"3179_CR18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase IIIOTSG (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"3179_CR19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","volume":"19","author":"KE Ensrud","year":"2004","unstructured":"Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research G (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259\u20131269","journal-title":"J Bone Miner Res"},{"key":"3179_CR20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","volume":"49","author":"PJ Kostenuik","year":"2011","unstructured":"Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS (2011) Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49:151\u2013161","journal-title":"Bone"},{"key":"3179_CR21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","volume":"49","author":"MS Ominsky","year":"2011","unstructured":"Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ (2011) Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 49:162\u2013173","journal-title":"Bone"},{"key":"3179_CR22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","volume":"59","author":"RM Zebaze","year":"2014","unstructured":"Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E (2014) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59:173\u2013179","journal-title":"Bone"},{"key":"3179_CR23","first-page":"47","volume":"10","author":"G Iolascon","year":"2013","unstructured":"Iolascon G, Napolano R, Gioia M, Moretti A, Riccio I, Gimigliano F (2013) The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies. Clin Cases Miner Bone Metab 10:47\u201351","journal-title":"Clin Cases Miner Bone Metab"},{"key":"3179_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227\u2013235","journal-title":"Osteoporos Int"},{"key":"3179_CR25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2010.04.594","volume":"47","author":"HK Genant","year":"2010","unstructured":"Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M, Libanati C (2010) Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 47:131\u2013139","journal-title":"Bone"},{"key":"3179_CR26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/GME.0b013e318267f909","volume":"20","author":"JA Simon","year":"2013","unstructured":"Simon JA, Recknor C, Moffett AH Jr, Adachi JD, Franek E, Lewiecki EM, McClung MR, Mautalen CA, Ragi-Eis S, Nicholson GC, Muschitz C, Nuti R, Torring O, Wang A, Libanati C (2013) Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause 20:130\u2013137","journal-title":"Menopause"},{"key":"3179_CR27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989\u2013995","journal-title":"Osteoporos Int"},{"key":"3179_CR28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/bonekey.2013.138","volume":"2","author":"JH Krege","year":"2013","unstructured":"Krege JH, Wan X, Lentle BC, Berger C, Langsetmo L, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Kreiger N, Olszynski WP, Josse RG, Goltzman D, CaMos Research G (2013) Fracture risk prediction: importance of age, BMD and spine fracture status. Bonekey Rep 2:404","journal-title":"Bonekey Rep"},{"key":"3179_CR29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/BMM:4:3:143","volume":"4","author":"M Bouxsein","year":"2006","unstructured":"Bouxsein M (2006) Biomechanics of osteoporotic fractures. Clin Rev Bone Miner Metab 4:143\u2013153","journal-title":"Clin Rev Bone Miner Metab"},{"key":"3179_CR30","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1359\/jbmr.080406","volume":"23","author":"TM Keaveny","year":"2008","unstructured":"Keaveny TM, Bouxsein ML (2008) Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res 23:1541\u20131547","journal-title":"J Bone Miner Res"},{"key":"3179_CR31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jbmr.2069","volume":"29","author":"DL Kopperdahl","year":"2014","unstructured":"Kopperdahl DL, Aspelund T, Hoffmann PF, Sigurdsson S, Siggeirsdottir K, Harris TB, Gudnason V, Keaveny TM (2014) Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scans. J Bone Miner Res 29:570\u2013580","journal-title":"J Bone Miner Res"},{"key":"3179_CR32","first-page":"S470","volume":"29","author":"JD Adachi","year":"2014","unstructured":"Adachi JD, Ho PR, Lin CJF, Bolognese MA, Bone HG, Hadji P, Papapoulos S, Recknor C, Daizadeh NS, Dakin P, Wagman RB, Ferrari S (2014) Evolution of subject characteristics in FREEDOM and its extension for up to 8 years. J Bone Miner Res 29:S470","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3179-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3179-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T09:13:14Z","timestamp":1599124394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3179-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["3179"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3179-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,12]]}}}